Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.

Period	Debt/Equity
2018-12-31	1.64
2019-12-31	0.97
2020-12-31	0.40
2021-12-31	0.44
2022-12-31	0.43
2023-12-31	1.50
2024-12-31	1.98

	A	B	C	D
1	Symbol	Price	Change	Volume
2	LQDA	$37.36	+0.00%	0.94M
3
4
5

Liquidia Corporation (LQDA) Debt to Equity Ratio

Debt to Equity Ratio Data

Get Liquidia Corporation Data in Excel

More LQDA Financial Data